World News

Rwanda genocide trial | Workplace safety

Posted by: The Conversation Global

Date: Saturday, 23 May 2020

 

Félicien Kabuga stands accused of financing imports of machetes to Rwanda ahead of the 1994 genocide. Machetes were the main weapon used to kill people. The 84-year-old Kabuga has been captured in France and appeared before a French court this week. What happens next is likely to be fraught with complications. Rwandan genocide survivors will want him to be prosecuted in Rwanda because they don’t trust the international justice system. But, writes Jonathan Beloff, this is unlikely to happen – for legal as well as political reasons.

South Africa has come up with a detailed plan for protecting workers against COVID-19 infections when the country resumes a big chunk of its economic activity. However, as Carin Runciman points out, these plans face two hurdles: government’s limited capacity to inspect and enforce the regulations; and the poor compliance culture among employers.

Moina Spooner

Commissioning Editor: East and Francophone Africa

Top Stories

A red marks the face of Felicien Kabuga, one of the last key suspects in the 1994 Rwandan genocide, on a wanted poster at the Genocide Fugitive Tracking Unit office in Kigali, Rwanda. Photo by SIMON WOHLFAHRT/AFP via Getty Images

Rwandans will want Félicien Kabuga tried at home. Why this won’t happen

Jonathan Beloff, SOAS, University of London

Though genocide survivors would ideally want Kabuga to be prosecuted in Rwanda, it won't be possible, for legal or political reasons.

Workers with face masks seen at The Hat Factory in Cape Town, South Africa. But most employers don’t abide by health and safety regulations. Nardus Engelbrecht/Gallo Images via Getty Images

Why easing the lockdown threatens to put workers in South Africa at risk

Carin Runciman, University of Johannesburg

Compliance with occupational health and safety requirements is already poor and few inspections of workplaces are being done.

Health + Medicine

What the phase 1 trials of the first COVID-19 vaccine really mean

Sanjay Mishra, Vanderbilt University

Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.

‘Anti-ageing’ protein shown to slow cell growth is key in longevity – new research

Charalampos (Babis) Rallis, University of Essex

This discovery could be important in helping increase human healthspan and longevity.

Energy + Environment

Why a 17% emissions drop does not mean we are addressing climate change

Larissa Basso, Stockholm University

Global quarantine is not a long-term solution – we still have a lot of work ahead.

Tiny plankton drive processes in the ocean that capture twice as much carbon as scientists thought

Ken Buesseler, Woods Hole Oceanographic Institution

Microscopic ocean phytoplankton feed a "biological pump" that carries carbon from the surface to deep waters. Scientists have found that this process stores much more carbon than previously thought.

En Français

Covid et baisse des émissions de CO₂ : une nouvelle étude fait le point secteur par secteur

Pep Canadell, CSIRO; Corinne Le Quéré, University of East Anglia; Felix Creutzig, Mercator Institute on Global Commons and Climate Change; Glen Peters, Center for International Climate and Environment Research - Oslo; Matthew William Jones, University of East Anglia; Pierre Friedlingstein, University of Exeter; Rob Jackson, Stanford University; Yuli Shan, University of Groningen

De tout récents travaux du Global Carbon Project montrent dans le détail les effets de la pandémie et du confinement sur l’économie mondiale.

Le tabac protège du Covid-19, vraiment ?

Philippe Bizouarn, Université de Paris; Élodie Giroux, Université Jean-Moulin Lyon 3

Si chez malades, le pourcentage de fumeurs était plus faible que dans la population générale, il ne faut pas crier au lien de cause à effet.

En español

La melatonina, guardián del cerebro frente al coronavirus

Alejandro Romero Martinez, Universidad Complutense de Madrid; Francisco López-Muñoz, Universidad Camilo José Cela

La melatonina tiene múltiples acciones antivirales. Los expertos barajan su uso como tratamiento complementario frente a la COVID-19.

COVID-19 y el lado oscuro de la promiscuidad de la vida

Juli Peretó, Universitat de València

Los virus han desempeñado un papel crucial en la evolución, como bien atestiguan las huellas que han dejado incrustadas en los genomas. Pero también son causantes de enfermedades.

 
 
 
 
 
 

EmbassyMedia - ራብዓይ ግንባር!

Dehai Events